. There is a wide variation in HBsAg prevalence in different geographical regions in India. Highest prevalence has been recorded in natives of Andamans and Arunachal Pradesh Population prevalence of chronic HCV infection in India is around 1 per cent. Prevalence of hepatitis C has been observed to be relatively higher in Punjab, Haryana, Andhra Pradesh, Puducherry, Arunachal Pradesh and Mizoram compared to other States. Besides the well known high risk groups like injecting drug users (IDUs), truckers, and attendees of sexually transmitted disease (STD) clinics, in persons suffering from thalassaemia, haemophilia and other disease conditions requiring blood products transfusion, different risk factors have been highlighted which are believed to have led to the relatively higher prevalence of the condition in particular areas. For example, history of surgery, dental treatment and unprotected sex (in Punjab) . Acute HEV has inordinately high mortality rate of 15 to 25 per cent in pregnant women in the third trimester 14 .
Spread of viruses causing hepatitis has three components, an infectious source, a susceptible host and an established route of transmission. Various strategies for control of viruses causing hepatitis would include control of infectious source, immunization of the host (susceptible subjects) and interruption of all routes of transmission ( Figure) .
Control of infectious source and providing free treatment of existing patient pool
Control of infectious source can be achieved for hepatitis B and C by treating the existing subjects infected with HBV and HCV so that viral load can decrease to undetectable levels, and the infection does not spread rampantly. However, the cost of treatment for chronic HBV and HCV infections is prohibitive for a large proportion of patients. There is a need to develop a mechanism to provide free drugs to needy patients, in similar lines to National AIDS Control Organization (NACO) providing free HIV drugs to patients infected with HIV. This is one of the most important ways to prevent further transmission of HBV and HCV and needs to be implemented on priority.
For hepatitis A and E, there are no specific treatments having a bearing on the control of infectious source. However, safe water and food and awareness on public health measures need to be rapidly implemented.
Immunization of the host (susceptible subjects)
The other strategy is to protect the susceptible host by immunization, and this is the most effective strategy. The hepatitis B vaccine has been included in the Global Alliance on Vaccines and Immunization (GAVI) since 2000. HBV vaccine had been included in the national immunization programmes of nearly 175 WHO member countries by the end of 2009 15 . In India, hepatitis B vaccination programme was initially launched in 2002 with gradual expansion to cover all districts in 10 States of the country in 2007-08 16 . However, still many challenges remain to be addressed including lower coverage with three doses of hepatitis B vaccine than similarly timed three doses of DPT vaccine. A review of the existing framework for vaccine distribution and immunization is urgently needed and targets to be set for achieving near 100 per cent coverage in the universal immunization programme (UIP) for hepatitis B by 2020.
Although health care expenditure in India is also gradually being increased through the years, yet, it is still low. Total expenditure on health care in India, taking both public, private and household out ofpocket (OOP) expenditure was about 4. 1 . In the absence of appropriate steps, epidemics of hepatitis A are likely to occur in the susceptible population with severity of the disease increasing with age. Although there is some evidence of changing epidemiology in select areas, mass or targetted HAV vaccination should not be recommended for India as a public health policy.
HEV vaccine is likely to be available soon in India. Pregnant women and patients with cirrhosis would be priority groups for HEV vaccination. However, several issues remain including lack of population data regarding disease incidence, mortality rate and disease burden and rate of clinical hepatitis E among pregnant women; duration of protection of the vaccine; protection against large viral load and/or severe disease; safety in pregnancy; effect on virus excretion not known. Besides there would be programmatic issues such as targeting vaccines to adults and pregnant women and cost. Currently there is no marketed vaccine for HCV.
Interruption of routes of transmission
Interruption of transmission of viral hepatitis can be achieved by education and increasing the awareness of the public and medical personnel; improved sanitation and safe drinking water (for HAV/HEV prevention); and emphasizing the importance of safe blood and injections.
Increasing the awareness of the public and medical personnel: Education of public and health care professionals will help in identification of persons at risk for viral hepatitis and ensure appropriate counselling, diagnosis, medical management, and treatment. In India, it has been reported that more than 93 per cent of injections are unsafe . There is an urgent need for implementing mandatory vaccination and immunization for all HCWs in India. There is also a need for strict implementation and monitoring of safe injection practices in Indian health care system.
World Hepatitis Day on 28
th July is one of eight official global public health campaigns marked by the World Health Organization 24 . December 4 is celebrated officially in Delhi as "Hepatitis Awareness Day" since 1998 and it plays an important role in spreading awareness amongst public and health care professionals about hepatitis in Delhi, India.
Improved sanitation and safe drinking water:
Improving sanitation and providing safe drinking water is important for preventing HAV and HEV. Blood safety is a challenge in India because of the high prevalence of HIV, HCV, and HBV, the relatively low percentage of volunteer donors and the lack of standardization of screening procedures among the multitude of blood collection centers 29, 30 . Centralized NAT screening centres are hugely successful all over the world. This tool could provide the next large step in improving the safety of blood supply in our country.
We have sufficient if not adequate data on the disease burden and modes of spread of viral hepatitis in India. It is time to act now. The goal of eradicating HBV is plausible, but every endeavour has to be pursued to make it become a reality by the year 2080. If we design our programme clearly, the target can be achieved in 65 years, with a new generation of immunized healthy babies growing up. Similarly, HAV vaccination strategies need to be revisited. India needs an HEV vaccine and its development and early availability should be made a priority. Education and awareness among public and health care workers about viral hepatitis need to be increased. Safe drinking water and sanitation should become a priority. A dedicated trained public health cadre for viral hepatitis as was done for HIV, is the need of the hour. Safe injection practices and blood safety are important components in viral hepatitis prevention. There is a need for National Viral Hepatitis Prevention and Management Strategy with focus on various aspects of viral hepatitis prevention and management.
Though there are still many challenges in prevention and eradication of viral hepatitis in India, if all the stakeholders come on a common platform and join hands and initiate a comprehensive action plan this year, we could achieve the targets of viral hepatitis eradication by 2080 and declare India 'Free of viral hepatitis'. 
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